Abstract:BACKGROUND & OBJECTIVE:Platinum-based chemotherapy regimens are better than other regimens when treating patients with advanced non-small cell lung cancer (NSCLC). The third generation of platinum-based regimens {NP [Navelbine (NVB), cisplatin (DDP)], TP (Taxol, DDP), GP (Gemzar, DDP)} is better than the second generation {MVP [mitomycin (MMC), desacetylvinblastin amide (VDS), DDP], MIP [MMC, ifosfamide (IFO), DDP], EP [etopside (VP-16), DDP], VDS+DDP}. This study was to compare the efficacy between the second and the third generations of platinum-based regimens combined with radiotherapy on advanced non-small cell lung cancer (NSCLC).METHODS:From Jul. 1999 to Dec. 2001, 47 pathologically confirmed advanced NSCLC patients received chemoradiotherapy: 24 received the second generation of platinum-based regimens, 23 received the third generation; all patients received routine external irradiation of (60)Co (65-76 Gy). Characteristics of the patients were comparable. Kaplan-Meier analysis was used to evaluate survival rates, and log-rank test to study differences between the 2 groups.RESULTS:The objective response rates were 41.7% in the second generation group, and 56.5% in the third generation group (Chi (2)=0.53, P=0.47). The median time to progression and median survival time were significantly longer in the third generation group than in the second generation group (12.6 months vs. 6.0 months, Chi(2)=6.93, P=0.01; 14.0 months vs. 9.0 months, Z=-2.17, P=0.03). The 1-, and 2-year survival rates were significantly higher in the third generation group than in the second generation group (56.3% vs. 30.7%, 15.6% vs. 0%, Chi(2)=6.59, P=0.01). The major adverse events were leukocytopenia, nausea and vomiting, radiation-induced esophagitis and pneumonia, which were tolerable.CONCLUSIONS:The third generation of platinum-based regimens in combination with radiotherapy for advanced non-small lung cancer may be more advantageous over the second generation of platinum-based regimens in prolonging survival of advanced NSCLC patients, which would be worth being studied further.

The Efficacy Compares of Platinum Regimen Chemotherapy among 60 Treat-naive Advanced Nonsmall Cell Lung Carcinoma Patients

Comparison of Cisplatin-Mitomycin-vinorelbine Versus Cisplatin-Mitomycin-vindesine Regimen for Treatment of Advanced Non-Small Cell Lung Cancer: a Report of 83 Patients

A Clinical Study on Efficacy and Toxicity of NP in Contrast to the MNP Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer

[Comparison of Treatment Efficacy of the Second and the Third Generations of Chemoradiotherapy Regimens Containing Platinum on Advanced Non-Small Cell Lung Cancer].

A Meta-analysis of Platinum Plus Taxanes Regimen on Treating Advanced Non-small Cell Lung Cancer

Efficacy of Third‐generation Chemotherapeutic Agents Combined with Cisplatin or Carboplatin in 3100 Chinese Patients with Advanced Non‐small‐cell Lung Cancer

[A Randomized Comparative Trial of Three Combined Regimens Containing Cisplatin for Treatment of Advanced Non-Small Cell Lung Cancer].

[Comparison of Cisplatin Combined with Gemcitabine Versus Cisplatin Combined with Vinorelbine Regimen for Treatment of Patients with Advanced Non-Small Cell Lung Cancer].

A Comparative Study for Vinorelbine with Cisplatin Plus Mitomycin and Vinorelbine with Cisplatin in Advanced Non-Small-cell Lung Cancer

[Comparative study on gemcitabine plus cisplatin and vinorelbine plus ifosfamide plus cisplatin combined chemotherapy in the treatment of advanced non-small cell lung cancer].

Three Cisplatin-Based Regimens in Treatment of Advanced Non-Small Cell Lung Cancer

Comparison of Short-term Efficacy between the NP and GP Regimens in the Treatment of Advanced Non-small-cell Lung Canaer

[Therapeutic efficacy of chemotherapy combined with radiotherapy in 527 patients with stage III and IV non-small cell lung cancer].

The application of different chemotherapy regimens in non-small cell lung cancer

Clinical Study of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin in Treatment of Patients with Advanced Non-Small-cell Lung Cancer

Comparison of Different Regimen in Treatment of Patients with Advanced Non-Small Cell Lung Cancer

[A Meta-Analysis of Pemetrexed Plus Platinum Chemotherapy Versus Gemcitabine Plus Platinum Chemotherapy for Advanced Non-Small Cell Lung Cancer].

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

Efficacy of Gemcitabine Combined with Different Platinum Agents for Early Treatment of Advanced NSCLC

Treatment of advanced non-small cell lung cancer with gemcitabine or docetaxel in combination with cisplatin:a systematic review

Triplet Platinum-Based Combination Sequential Chemotherapy Improves Survival Outcome And Quality Of Life Of Advanced Non-Small Cell Lung Cancer Patients